CEFOPERAZONE PHARMACOKINETICS IN PATIENTS WITH LIVER-CIRRHOSIS - A PREDICTIVE VALUE OF THE UJOVIRIDIN TEST

  • 1 February 1989
    • journal article
    • research article
    • Vol. 27  (2) , 82-87
Abstract
Pharmacokinetics of cefoperazone was studied in 10 healthy volunteers and in 11 patients with liver cirrhosis. In the same persons, we also examined the clearance of ujoviridin-a preparation of indocyanine green. Within 12 h, 31.8 (.+-. 7.6)% of the 2 g dose of cefoperazone was eliminated in the urine of healthy persons and 74.3 (.+-. 7.9)% (mean .+-. SD) was eliminated in the urine of cirrhotics. The biological half-life (.beta.-phase) of cefoperazone in healthy volunteers and in cirrhotics was 1.77 (.+-. 0.25) and 4.29 (.+-. 1.16) h, total clearance 1.009 (.+-. 0.187) and 0.583 (.+-. 0.169) ml/s and hepatic clearance 0.694 (.+-. 0.174) and 0.152 (.+-. 0.079) ml/s, respectively. The differences are statistically significant (p < 0.001). We also found good correlation between total clearance of cefoperazone and clearance of ujoviridin (r = 0.842) and even better between hepatic clearance of cefoperazone and ujoviridin clearance (r = 0.957), both statistically significant. The findings suggest that the dosage of cefoperazone should be reduced in patients with liver cirrhosis and that the ujoviridin clearance test is a good indicator of impaired cefoperazone elimination.

This publication has 3 references indexed in Scilit: